1.Alternative Name:B29,Ig-beta；B29; B29B-cell-specific glycoprotein B29; B-cell antigen receptor complex-associated protein beta chain; CD79B antigen (immunoglobulin-associated beta); CD79b antigen; CD79b molecule, immunoglobulin-associated beta; CD79B; IGB; IGBAGM6; Ig-beta; Immunoglobulin-associated B29 protein
2.Target:CD79b
3.Source:Human CD79b was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence:Ala29-Asp159
5.Protein structure:P40259hFC
6.Molecular Characterization:The protein has a calculated MW of 41kDa.The reducing (R) heterodimer protein migrates as 50-70 kDa due to glycosylation
7.Purity:SDS-PAGE>95%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
Note:For research use only .


11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.

    

13.ELISA

When Recombinant Human CD79b/hFC Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-human CD79b (Polatuzumab) that produces 50% of the optimal binding response is approximately 0.1 ug/ml.

14.SPR

Recombinant Human CD79b/hFC Protein（Cat.No.B21660303）captured on CM5 chip , can bind Anti-human CD79b (Polatuzumab )（Cat.No.B790301）with a KD constant of 1.39E-08M, determined in a SPR assay .